Trial Profile
A phase II, randomized, double blind, placebo controlled, parallel group study to evaluate safety and efficacy of UK-432,097 dry powder for inhalation in adults with moderate to severe chronic obstructive pulmonary disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Uk 432097 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Aug 2019 Planned number of patients changed from 240 to 600.
- 17 Mar 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 03 Nov 2008 Actual patient number (71) added as reported by ClinicalTrials.gov.